Working… Menu

Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00180739
Recruitment Status : Terminated (Recruitment not possible worldwide)
First Posted : September 16, 2005
Last Update Posted : May 14, 2019
Information provided by (Responsible Party):
Imperial College London

Brief Summary:
The study objective is to develop data for the safety of pregnancies after thermal ablation of uterine fibroids by MR guided Focused Ultrasound using the Ex Ablate 2000 system.

Condition or disease Intervention/treatment Phase
Uterine Fibroids Pregnancy Procedure: Magnetic Resonance Guided Focused Ultrasound Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies
Actual Study Start Date : April 2004
Actual Primary Completion Date : August 2005
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Primary Outcome Measures :
  1. Pregnancy outcomes in women who have received treatment with MRgFUS

Secondary Outcome Measures :
  1. Efficacy of MRgFUS as judged by HRQOL questionnaires

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 1. Subject with uterine fibroids, who desire pregnancy within 12 months and has the one of the following criteria: Women 20-40 age. Women age < 46 years old who plan to have egg donation. Women above 38 should test for normal ovarian function as judged by endocrinological evaluation.

If the couple has failed to conceive for more that 1 year, the woman should test for normal ovarian function as judged by endocrinological evaluation, and the male must have adequate sperm test.

Women undergoing fertility treatment or plan to have sperm donation.

  • 2. Use or non use of non-steroidal treatments for excessive vaginal bleeding such as antifibrinolytic agents (e.g. Tranexamic acid) or non-steroidal anti-inflammatory drugs (e.g. Mefanamic Acid) has been maintained for the three months prior to the planned date of the study procedure and the patient has agreed to maintain this use or non-use through the 6-month follow-up period.
  • 3. Clinically normal PAP smear within timing of National Guidelines in the country of the clinical site.
  • 4. Able and willing to give consent and able to attend all study visits
  • 5. Able to communicate sensations during the MRgFUS procedure
  • 6. Having uterine fibroids that are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
  • 7. Tumor(s) are clearly visible on non-contrast MRI.
  • 8. Largest fibroid 8 cm in diameter or 12 cm if receiving GnRH

Exclusion Criteria:

  • 1. Patient is pregnant as confirmed by pregnancy test at time of screening
  • 2. Uterine size >20 weeks as evaluated by US or MR.
  • 3. Patients who are considered "high risk pregnancy" due to uterine factors (e.g. abnormal uterus, uterine scars, cerclage) except fibroids.
  • 4. Patients with fibroid that is more than 50% sub-mucosal or with hysteroscopically resectable
  • 5. Patients with adenomyosis
  • 6. Patient is on dialysis
  • 7. Hematocrit is < 25
  • 8. Patient has hemolytic anemia
  • 9. Patient has unstable cardiac status including: § Unstable angina pectoris on medication§ Documented myocardial infarction within 6 months of protocol entry§ Congestive heart failure requiring medication (other than diuretic)§ Currently taking anti-arrhythmic drugs§ Severe hypertension (diastolic BP>100 on medication)§ Presence of cardiac pacemaker
  • 10. Patient has an ASA score of >2
  • 11. Patient has severe cerebrovascular disease (multiple CVA or CVA within 6 months)
  • 12. Patient is on anti-coagulation therapy or has an underlying bleeding disorder
  • 13. Evidence of uterine pathology other than leiomyoma
  • 14. Patient has an active pelvic infection or history of pelvic inflammatory disease
  • 15. Patient has an undiagnosed pelvic mass outside the uterus.
  • 16. Patient weight >110 kg
  • 17. Subject with extensive abdominal scarring in an area of the abdomen directly anterior to the treatment area.
  • 18. Subject with standard contraindications for MR imaging such as non-MRI compatable implanted metallic devices.
  • 19. Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist).
  • 20. Individuals who are not able or willing to tolerate the required prolonged stationary prone position during treatment (approximately 3 hours.)
  • 21. Patient with an intrauterine contraceptive device anywhere in the treatment beam path.
  • 22. Women who are breast feeding.
  • 23. Five or more fibroids, bigger then 3cm diameter, each

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00180739

Layout table for location information
United Kingdom
St Mary's Hospital
London, United Kingdom, W2 1NY
Sponsors and Collaborators
Imperial College London
Layout table for investigator information
Principal Investigator: Wady Gedroyc St Mary's NHS Trust
Layout table for additonal information
Responsible Party: Imperial College London Identifier: NCT00180739    
Other Study ID Numbers: UF004
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019
Keywords provided by Imperial College London:
MR guided FUS
Uterine Fibroids
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases